[Dynamics of serum HCV RNA levels during IFN therapy in patients with chronic hepatitis C for prediction of outcome of IFN therapy and beneficial dosing].
For beneficial Interferon therapy to patients with chronic hepatitis C, we assess the change of serum HCV RNA levels during the early phase of IFN therapy, comparing the schedule of IFN beta 3 MU x 2 times per day and daily administration of IFN alpha 2b 10 MU once per day. During first 2 weeks, decrease in serum HCV RNA levels was significantly faster in IFN beta 2 times per day than alpha 2b. We concluded that the administration of IFN beta 2 times per day for 2 weeks followed by IFN alpha 10 MU will be suitable for IFN induction therapy.
Iwabuchi
S
S
Center for Digestive and Liver Disease, Ofuna Chyuo Hospital.
Takatsuka
K
K
D015415:Biomarkers / Q000097:blood; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D016899:Interferon-beta / Q000008:administration & dosage*; D012367:RNA, Viral / Q000097:blood*; D011994:Recombinant Proteins; D016896:Treatment Outcome; D019562:Viral Load
D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D016899:Interferon-beta